Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Rutgers, The State University of New Jersey
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Istanbul Medipol University Hospital
Achieve Life Sciences
People's Hospital of Xinjiang Uygur Autonomous Region
National Institutes of Health Clinical Center (CC)
Institut Claudius Regaud
National Institutes of Health Clinical Center (CC)
Vastra Gotaland Region
Vastra Gotaland Region
AstraZeneca
University of Utah
Bristol-Myers Squibb
St. Olavs Hospital
Ohio State University Comprehensive Cancer Center
Montefiore Medical Center
Montefiore Medical Center
Montefiore Medical Center
Ohio State University Comprehensive Cancer Center
Travera Inc
Loyola Marymount University
The First Hospital of Hebei Medical University
The Methodist Hospital Research Institute
Montefiore Medical Center
Sandoz
Fred Hutchinson Cancer Center
Henan Cancer Hospital
IO Biotech
AstraZeneca
Novartis
Amgen
Gustave Roussy, Cancer Campus, Grand Paris
AstraZeneca
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Affiliated Hospital of Nantong University
Hoffmann-La Roche
Brown University
BeOne Medicines
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
Novartis
Institut Cancerologie de l'Ouest
University of California, Irvine
Shanxi Province Cancer Hospital
University of Chicago
Centre Hospitalier Universitaire de Nice